PHIA Koninklijke Philips N.V.

Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare

Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare

April 18, 2023

Latest clinical data set of 200,000 patients from over 200 hospitals, includes pandemic data for a broader and dependable foundation for machine learning

Amsterdam, the Netherlands and Cambridge, MA, USA – (NYSE: PHG, AEX: PHIA), a health technology provider, today announced an expansion of its initiative with the at the Massachusetts Institute of Technology (MIT) to allow health care researchers access to a new critical care data set to help advance machine learning and artificial intelligence (AI) in healthcare. The updated eICU Collaborative Research Database (eICU-CRD) includes de-identified data of 200,000 critical care patients, including patients who were impacted by COVID-19. The broader and clinically dependable data set will support the development of solutions that improve patient care and clinical outcomes.

During the COVID-19 pandemic, eICU and critical care saw a dramatic increase of patients and unique challenges in the way that care was provided, prompting Philips and IMES to expand the original data set, first released in 2016. The new secure database includes de-identified and detailed clinical information such as vital signs, pharmacy and medication orders, laboratory results, diagnoses, and novel severity of illness scores. The dataset gives comprehensive insights on patient treatments, co-morbidities, readmissions, and clinical outcomes.

Researchers at Philips and the Laboratory of Computational Physiology within IMES will grant researchers around the world access to the data to help develop advanced algorithms and provide new insights on critical care. The Laboratory of Computational Physiology will continue to serve as the academic research hub for the initiative and will provide and maintain access, as well as help educate researchers on the database and offer a platform for collaboration. The database is available for medical research, to those who are credentialed, who take human subjects training, and who agree to a data use agreement.

“The database, which includes patient information from 2020 and 2021, now contains significant overlap with the Covid-19 pandemic, yielding valuable patient data for research,” said Leo Anthony Celi, principal research scientist and clinical research director at the Laboratory of Computational Physiology at IMES. “This updated database is a vital resource for education, including in many courses at institutions like Harvard, MIT and Stanford; and training, as well as low-resource institutions,” said Jesse D. Raffa, research scientist in the Lab for Computational Physiology at IMES.

The eICU-CRD is the only dataset containing detailed critical care data from over 200 hospitals across the U.S., representing many ‘real-world’ challenges for successful deployment of algorithms and models, which are often not readily apparent in single-center datasets. Unlike other organizations that do not share data or only share single source data sets, Philips shares its data with credentialled researchers to help advance AI for improving outcomes in human health. More than 3,000 users have used the original database with citations in over 660 published academic research papers, including in Nature, The New England Journal of Medicine and the Journal of the American Medical Association.

“This initiative demonstrates our commitment to advancing machine learning and AI efforts, by making eICU data available for global research initiatives,” said Shiv Gopalkrishnan, General Manager of EMR & Care Management at Philips. “This is how we can enhance patient care and improve clinical outcomes: liberating and connecting data across systems and applications with integrated devices, systems and informatics, which can inform research with patient insights that can help clinicians make the right decision at the right time for their patients.”

For further information, please contact:





Silvie Casanova

Philips North America

Tel.

E-mail:

Anna Hogrebe

Philips Global Press Office

Tel.:

E-mail:



Mindy Blodgett

MIT IMES

Tel.

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About IMES

The Institute for Medical Engineering and Science (IMES) at the Massachusetts Institute of Technology (MIT) is an inclusive community of students, administrative staff, research staff, and faculty who research, work, educate, and learn, at the convergence of engineering, science, and medicine to transform human health for all. More about IMES can be found at . 

Attachment



EN
18/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips announces 5,000th Zenition mobile C-arm system installation, a...

Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide October 8, 2025 Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at Kolín Regional Hospital in the Czech Republic. Since its la...

 PRESS RELEASE

Philips unveils latest CT and MR innovations in radiation therapy, adv...

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term valuePhilips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands – At the American Society for Radiation Oncology () 2025 Annual Meeting, (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips joins Optum Healthcare’s network as a preferred provider in th...

Philips joins Optum Healthcare’s network as a preferred provider in the USA September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of cardiac conditions and timely cli...

 PRESS RELEASE

Philips intends to extend maturity of forward purchases of 4 million s...

Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans September 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this . For further information, please contact:Michael FuchsPhil...

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch